TrialJournal for immunotherapy of cancer2022

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.

Yoon-Koo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.